

# Daniel Gaudet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4878033/publications.pdf>

Version: 2024-02-01

258  
papers

23,343  
citations

10389

72  
h-index

8396

147  
g-index

269  
all docs

269  
docs citations

269  
times ranked

21589  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1864-1872.	1.8	19
2	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	2.2	78
3	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , 2022, 38, 311-319.	1.7	7
4	Effectiveness of a Novel 3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. <i>JAMA Network Open</i> , 2022, 5, e2141898.	5.9	14
5	Lomitapide Reduces LDL-C and Favourably Affects Carotid Intima Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. <i>Journal of Clinical Lipidology</i> , 2022, 16, e18-e19.	1.5	0
6	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. <i>Advances in Therapy</i> , 2022, 39, 1857-1870.	2.9	7
7	Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. <i>Circulation</i> , 2022, 145, 1377-1386.	1.6	81
8	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. <i>Archives of Medical Science</i> , 2022, 18, 285-292.	0.9	13
9	Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. <i>Future Cardiology</i> , 2022, 18, 507-518.	1.2	3
10	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2022, 16, 617-625.	1.5	15
11	Palmar Striated Xanthomas in Clinical Practice. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.2	0
12	A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents. <i>Molecular Psychiatry</i> , 2021, 26, 3795-3805.	7.9	14
13	Development and Standardization of Rapid and Efficient Seed Germination Protocol for <i>Cannabis sativa</i> . <i>Bio-protocol</i> , 2021, 11, e3875.	0.4	6
14	SARS-CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. <i>American Journal of Hypertension</i> , 2021, 34, 367-376.	2.0	42
15	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 669.	2.4	11
16	Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability. <i>Journal of Medical Genetics</i> , 2021, 58, 653-665.	3.2	12
17	Genetics of symptom remission in outpatients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 10847.	3.3	7
18	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	11.4	109

#	ARTICLE	IF	CITATIONS
19	Inhibition of Angiotensin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 193-195.	2.8	36
20	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	10.7	218
21	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
22	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet</i> , 2021, 398, 1713-1725.	13.7	142
23	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 64.	2.4	9
24	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	11.4	114
25	DNA methylation at <i>LRP1</i> gene locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels. <i>Journal of Developmental Origins of Health and Disease</i> , 2020, 11, 369-378.	1.4	8
26	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19.	0.8	21
27	Relative effect of hypertriglyceridemia on non-HDL-C and apolipoprotein B as cardiovascular disease risk markers. <i>Journal of Clinical Lipidology</i> , 2020, 14, 825-836.	1.5	6
28	Adiposity-related insulin resistance and thickness of the cerebral cortex in middle-aged adults. <i>Journal of Neuroendocrinology</i> , 2020, 32, e12921.	2.6	9
29	Evinacumab in Patients with Refractory Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 2307-2319.	27.0	186
30	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. <i>Atherosclerosis</i> , 2020, 310, 54-63.	0.8	12
31	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	2.2	188
32	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 1317-1327.	27.0	108
33	Comparison of the Effect of Hypertriglyceridemia on Non-HDL-Cholesterol and Apolipoprotein B as Cardiovascular Disease Risk Markers—, a. <i>Journal of Clinical Lipidology</i> , 2020, 14, 571-572.	1.5	0
34	Evinacumab for Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020, 383, 711-720.	27.0	413
35	Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Pre <sup>β</sup> -HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 3062-3064.	2.8	5
36	Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. <i>Lipids in Health and Disease</i> , 2020, 19, 98.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , 2020, 19, 117.	3.0	3
38	Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa056.	0.2	14
39	The burden of familial chylomicronemia syndrome in Canadian patients. <i>Lipids in Health and Disease</i> , 2020, 19, 120.	3.0	15
40	Transient expression of the <i>UGT2G1</i> gene in <i>Cannabis sativa</i> varieties. <i>Plant Signaling and Behavior</i> , 2020, 15, 1780037.	2.4	21
41	Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 76, 131-142.	2.8	96
42	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 403-414.	5.0	3
43	Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz010.	0.2	4
44	Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia. <i>Endocrine Journal</i> , 2020, 67, 1157-1161.	1.6	3
45	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542.	27.0	359
46	Free glycerol correlate with post-heparin lipoprotein lipase activity and contribute to differentiate familial vs. multifactorial chylomicronemia. <i>Journal of Clinical Lipidology</i> , 2019, 13, e26.	1.5	0
47	Novel Genetic Locus of Visceral Fat and Systemic Inflammation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3735-3742.	3.6	11
48	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. <i>PLoS ONE</i> , 2019, 14, e0218115.	2.5	18
49	Sex Differences in Blood Pressure Hemodynamics in Middle-Aged Adults With Overweight and Obesity. <i>Hypertension</i> , 2019, 74, 407-412.	2.7	8
50	Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity. <i>Journal of Clinical Lipidology</i> , 2019, 13, e25-e26.	1.5	1
51	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. <i>CJC Open</i> , 2019, 1, 190-197.	1.5	2
52	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2248-2260.	2.4	60
53	Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). <i>American Journal of Cardiology</i> , 2019, 124, 1876-1880.	1.6	23
54	Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 403-414.	2.4	16

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662.	3.7	292
56	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. <i>Journal of the Endocrine Society</i> , 2019, 3, 2397-2410.	0.2	32
57	Visceral fat-related systemic inflammation and the adolescent brain: a mediating role of circulating glycerophosphocholines. <i>International Journal of Obesity</i> , 2019, 43, 1223-1230.	3.4	20
58	Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management. <i>Journal of Clinical Lipidology</i> , 2018, 12, 254-263.	1.5	18
59	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 920-927.e4.	1.5	97
60	Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". <i>Circulation</i> , 2018, 137, 641-642.	1.6	1
61	Roundtable on etiology of familial chylomicronemia syndrome. <i>Journal of Clinical Lipidology</i> , 2018, 12, 5-11.	1.5	16
62	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , 2018, 64, 355-362.	3.2	47
63	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. <i>Nature Reviews Cardiology</i> , 2018, 15, 9-19.	13.7	105
64	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1553-1563.	1.7	105
65	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , 2018, 277, 419-424.	0.8	18
66	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	13.7	1,179
67	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1210-1214.	1.7	62
68	Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome. <i>BMC Medical Genetics</i> , 2018, 19, 130.	2.1	1
69	Surviving Familial Hypercholesterolemia without Coronary Artery Disease: A Unique Phenomenon Associated with Newly Identified Biological and Genetic Markers. <i>Atherosclerosis Supplements</i> , 2018, 32, 51.	1.2	0
70	Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS. <i>Journal of Clinical Lipidology</i> , 2018, 12, 537.	1.5	13
71	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. <i>Journal of Lipid Research</i> , 2018, 59, 1529-1535.	4.2	22
72	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1199-1207.	1.5	24

#	ARTICLE	IF	CITATIONS
73	Cohort Profile: The Saguenay Youth Study (SYS). <i>International Journal of Epidemiology</i> , 2017, 46, dyw023.	1.9	47
74	Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. <i>European Heart Journal</i> , 2017, 38, ehw135.	2.2	38
75	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 872-882.	1.7	34
76	Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5 years of age. <i>Epigenetics</i> , 2017, 12, 616-625.	2.7	38
77	Gene Expression Signature of Platelet Count in Lipoprotein Lipase Deficiency. <i>Journal of Clinical Lipidology</i> , 2017, 11, 795.	1.5	1
78	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 359-366.	1.6	84
79	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). <i>Atherosclerosis</i> , 2017, 263, e10.	0.8	23
80	Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1162-1170.	2.8	42
81	The odyssey apprise trial: rationale, design and interim data. <i>Atherosclerosis</i> , 2017, 263, e25.	0.8	0
82	First interim results of the global, longitudinal, pharmaco-epidemiologic, observational registry on gene therapy in the management of lipoprotein lipase deficiency (geniall). <i>Atherosclerosis</i> , 2017, 263, e66-e67.	0.8	1
83	ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2017, 377, 296-297.	27.0	258
84	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2017, 136, 332-335.	1.6	103
85	Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency. <i>Journal of Clinical Lipidology</i> , 2017, 11, 797-798.	1.5	14
86	Predicting Cardiovascular Events in Familial Hypercholesterolemia: Validation of the Montreal-FH-SCORE. <i>Journal of Clinical Lipidology</i> , 2017, 11, 781.	1.5	0
87	Characterizing Familial Chylomicronemia Syndrome: Baseline data of the APPROACH Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 816.	1.5	1
88	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1161-1167.e3.	1.5	42
89	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017, 119, 40-46.	1.6	116
90	Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. <i>International Journal of Cardiology</i> , 2017, 228, 754-760.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients. PLoS ONE, 2017, 12, e0169939.	2.5	9
92	Novel therapies for severe dyslipidemia originating from human genetics. Current Opinion in Lipidology, 2016, 27, 112-124.	2.7	18
93	Association Between Frequent Gene-Smoking Interactions And Plasma Apolipoprotein B Levels Among Low-Risk Individuals. Journal of Clinical Lipidology, 2016, 10, 671-672.	1.5	0
94	Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. Journal of Clinical Lipidology, 2016, 10, 680-681.	1.5	25
95	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology, 2016, 223, 750-757.	1.7	54
96	Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. Journal of Clinical Lipidology, 2016, 10, 715.	1.5	8
97	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
98	Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. Human Gene Therapy, 2016, 27, 916-925.	2.7	75
99	Glycerophosphocholine Metabolites and Cardiovascular Disease Risk Factors in Adolescents. Circulation, 2016, 134, 1629-1636.	1.6	55
100	Genetic and Functional investigation of LPL Independent Pathways of TG-Rich Lipoproteins Catabolism in Severe Hypertriglyceridemia and Chylomicronemia. Journal of Clinical Lipidology, 2016, 10, 664.	1.5	0
101	Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension. Hypertension Research, 2016, 39, 467-474.	2.7	6
102	Epigenetic and genetic variations at the <i>TNNT1</i> gene locus are associated with HDL-C levels and coronary artery disease. Epigenomics, 2016, 8, 359-371.	2.1	26
103	The Diacylglycerol Acyltransferase 1 Inhibitor, Pradigastat, Was Well Tolerated in a 52-Week Clinical Trial in FCS Patients. Journal of Clinical Lipidology, 2015, 9, 450.	1.5	3
104	Gene-based therapies in lipidology. Current Opinion in Lipidology, 2015, 26, 553-565.	2.7	19
105	CYP17A1 and Blood Pressure Reactivity to Stress in Adolescence. International Journal of Hypertension, 2015, 2015, 1-9.	1.3	6
106	Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Journal of Lipids, 2015, 2015, 1-10.	4.8	10
107	Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids in Health and Disease, 2015, 14, 8.	3.0	83
108	The effect of an apolipoprotein A-1 containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia. American Heart Journal, 2015, 169, 736-742.e1.	2.7	59



#	ARTICLE	IF	CITATIONS
109	A study in familial hypercholesterolemia suggests reduced methylomic plasticity in men with coronary artery disease. <i>Epigenomics</i> , 2015, 7, 17-34.	2.1	17
110	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2015, 373, 438-447.	27.0	445
111	Pradigastat Did Not Increase Fecal Bile Acids in Patients with Familial Chylomicronemia Syndrome After 52 Weeks. <i>Journal of Clinical Lipidology</i> , 2015, 9, 454-455.	1.5	0
112	Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. <i>Journal of Clinical Lipidology</i> , 2015, 9, 741-750.	1.5	42
113	Layered genetic control of DNA methylation and gene expression: a locus of multiple sclerosis in healthy individuals. <i>Human Molecular Genetics</i> , 2015, 24, 5733-5745.	2.9	26
114	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3140-3148.	3.6	198
115	Prenatal exposure to cigarette smoke interacts with <i>OPRM1</i> to modulate dietary preference for fat. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 38-45.	2.4	20
116	Prenatal Exposure to Maternal Cigarette Smoking and DNA Methylation: Epigenome-Wide Association in a Discovery Sample of Adolescents and Replication in an Independent Cohort at Birth through 17 Years of Age. <i>Environmental Health Perspectives</i> , 2015, 123, 193-199.	6.0	178
117	<i>LRP1B</i> , <i>BRD2</i> and <i>CACNA1D</i> : new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia. <i>Epigenomics</i> , 2015, 7, 1111-1122.	2.1	24
118	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2015, 385, 331-340.	13.7	615
119	Association of <i>CTRC</i> and <i>SPINK1</i> gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency. <i>Frontiers in Genetics</i> , 2014, 5, 90.	2.3	11
120	Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. <i>Epigenetics</i> , 2014, 9, 718-729.	2.7	57
121	Genealogical analysis as a new approach for the investigation of drug intolerance heritability. <i>European Journal of Human Genetics</i> , 2014, 22, 916-922.	2.8	3
122	Targeting <i>APOC3</i> in the Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 2200-2206.	27.0	376
123	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2525-2540.	2.8	192
124	Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors. <i>Nature Medicine</i> , 2014, 20, 578-579.	30.7	2
125	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1471-1481.	1.7	93
126	The potential applications of Apolipoprotein E in personalized medicine. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 154.	3.4	40



#	ARTICLE	IF	CITATIONS
127	Epigenetic dysregulation of the IGF system in placenta of newborns exposed to maternal impaired glucose tolerance. <i>Epigenomics</i> , 2014, 6, 193-207.	2.1	37
128	Immune Responses to Intramuscular Administration of Alipogene Tiparovec (AAV1-LPL <sup>S447X</sup> ) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy. <i>Human Gene Therapy</i> , 2014, 25, 180-188.	2.7	118
129	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150Âmg Every Two Weeks Dosing from Phase 2) <i>Tj ETQq1 1 0:Z84314 rg88 /Ove</i>	8.6	22
130	<i>ADRB3</i> gene promoter DNA methylation in blood and visceral adipose tissue is associated with metabolic disturbances in men. <i>Epigenomics</i> , 2014, 6, 33-43.	2.1	41
131	An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency. <i>Journal of Clinical Lipidology</i> , 2014, 8, 353-354.	1.5	1
132	Efficacy and long-term safety of alipogene tiparovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. <i>Gene Therapy</i> , 2013, 20, 361-369.	4.5	336
133	Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. <i>Diabetes Care</i> , 2013, 36, 2836-2842.	8.6	22
134	Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 408-413.	1.5	15
135	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. <i>Lancet</i> , The, 2013, 381, 40-46.	13.7	624
136	Lipoprotein Lipase Deficiency Clinical Biomarkers*. <i>Journal of Clinical Lipidology</i> , 2013, 7, 241.	1.5	0
137	Prenatal Exposure to Maternal Cigarette Smoking is Associated with Parasympathetic Predominance and Higher Dietary Fat Intake in Adolescence. <i>Canadian Journal of Diabetes</i> , 2013, 37, S266-S267.	0.8	0
138	Gestational Diabetes Mellitus Epigenetically Predominantly Affects Genes Involved in Metabolic Diseases. <i>Canadian Journal of Diabetes</i> , 2013, 37, S241.	0.8	1
139	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. <i>Molecular Therapy</i> , 2013, 21, 266-268.	8.2	12
140	A largely random AAV integration profile after LPLD gene therapy. <i>Nature Medicine</i> , 2013, 19, 889-891.	30.7	150
141	Medical resource use and costs associated with chylomicronemia. <i>Journal of Medical Economics</i> , 2013, 16, 657-666.	2.1	14
142	Adaptations of placental and cord blood <i>ABCA1</i> DNA methylation profile to maternal metabolic status. <i>Epigenetics</i> , 2013, 8, 1289-1302.	2.7	86
143	FTO, obesity and the adolescent brain. <i>Human Molecular Genetics</i> , 2013, 22, 1050-1058.	2.9	46
144	Prenatal Exposure to Maternal Cigarette Smoking, Amygdala Volume, and Fat Intake in Adolescence. <i>JAMA Psychiatry</i> , 2013, 70, 98.	11.0	60

#	ARTICLE	IF	CITATIONS
145	Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. <i>Epigenetics</i> , 2013, 8, 935-943.	2.7	217
146	Prevalence of Lifestyle Risk Factors in Myotonic Dystrophy Type 1. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 42-47.	0.5	27
147	Clustering of the Metabolic Syndrome Components in Adolescence: Role of Visceral Fat. <i>PLoS ONE</i> , 2013, 8, e82368.	2.5	16
148	Routine Clinical Measures of Adiposity as Predictors of Visceral Fat in Adolescence: A Population-Based Magnetic Resonance Imaging Study. <i>PLoS ONE</i> , 2013, 8, e79896.	2.5	23
149	Gene therapy for lipoprotein lipase deficiency. <i>Current Opinion in Lipidology</i> , 2012, 23, 310-320.	2.7	124
150	On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs). <i>Clinical Trials</i> , 2012, 9, 265-271.	1.6	6
151	Effect of Alipogene Tiparovec (AAV1-LPL <sup>S447X</sup> ) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1635-1644.	3.6	146
152	Sex Differences in the Contributions of Visceral and Total Body Fat to Blood Pressure in Adolescence. <i>Hypertension</i> , 2012, 59, 572-579.	2.7	50
153	Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. <i>Epigenomics</i> , 2012, 4, 623-639.	2.1	44
154	Genetic mapping of habitual substance use, obesity-related traits, responses to mental and physical stress, and heart rate and blood pressure measurements reveals shared genes that are overrepresented in the neural synapse. <i>Hypertension Research</i> , 2012, 35, 585-591.	2.7	37
155	Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2012, 126, 2283-2292.	1.6	271
156	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 29-36.	13.7	527
157	Increased frequency of DRB1*11:01 in anti-“hydroxymethylglutarylâ€œcoenzyme A reductaseâ€œ-associated autoimmune myopathy. <i>Arthritis Care and Research</i> , 2012, 64, 1233-1237.	3.4	126
158	Angiographically-assessed coronary artery disease associates with HDL particle size in women. <i>Atherosclerosis</i> , 2012, 223, 359-364.	0.8	9
159	The DGAT1 Inhibitor LCQ908 Decreases Triglyceride Levels in Patients with the Familial Chylomicronemia Syndrome. <i>Journal of Clinical Lipidology</i> , 2012, 6, 266-267.	1.5	30
160	<i>ABCA1</i> gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. <i>Epigenetics</i> , 2012, 7, 464-472.	2.7	114
161	Genome-Wide Scan for Loci of Adolescent Obesity and Their Relationship with Blood Pressure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E145-E150.	3.6	50
162	Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 56-64.	3.4	110

#	ARTICLE	IF	CITATIONS
163	Salivary pH as a marker of plasma adiponectin concentrations in Women. <i>Diabetology and Metabolic Syndrome</i> , 2012, 4, 4.	2.7	14
164	Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. <i>Arthritis Care and Research</i> , 2012, 64, 269-272.	3.4	177
165	Etiology and risk of lactescent plasma and severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, 37-44.	1.5	54
166	Contribution of adiponectin to the cardiometabolic risk of postmenopausal women with loss-of-function lipoprotein lipase gene mutations. <i>Menopause</i> , 2011, 18, 558-562.	2.0	4
167	Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 454-454.	8.2	0
168	Metabolic syndrome and oral markers of cardiometabolic risk. <i>Journal of the Canadian Dental Association</i> , 2011, 77, b125.	0.6	12
169	Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. <i>European Journal of Human Genetics</i> , 2010, 18, 342-347.	2.8	15
170	Fine Mapping of the Insulin-Induced Gene 2 Identifies a Variant Associated With LDL Cholesterol and Total Apolipoprotein B Levels. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 454-461.	5.1	7
171	Dyslipidemia of Mothers With Familial Hypercholesterolemia Deteriorates Lipids in Adult Offspring. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2673-2677.	2.4	49
172	From Clinical Sites to Biorepositories: Effectiveness in Blood Sample Management. <i>Biopreservation and Biobanking</i> , 2010, 8, 193-196.	1.0	0
173	Functional Variation in the Androgen-Receptor Gene Is Associated With Visceral Adiposity and Blood Pressure in Male Adolescents. <i>Hypertension</i> , 2010, 55, 706-714.	2.7	61
174	Decreased NKCC1 Activity in Erythrocytes From African Americans With Hypertension and Dyslipidemia. <i>American Journal of Hypertension</i> , 2010, 23, 321-326.	2.0	9
175	Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. <i>Atherosclerosis Supplements</i> , 2010, 11, 55-60.	1.2	110
176	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2010, 375, 998-1006.	13.7	813
177	Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 742-747.	1.5	20
178	Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels. <i>Journal of Lipid Research</i> , 2009, 50, 1109-1119.	4.2	20
179	A Common Variant of the <i>FTO</i> Gene Is Associated With Not Only Increased Adiposity but Also Elevated Blood Pressure in French Canadians. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 260-269.	5.1	84
180	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2009, 41, 71-76.	21.4	448

#	ARTICLE	IF	CITATIONS
181	Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3597-3612.	8.2	37
182	Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis. <i>PLoS ONE</i> , 2009, 4, e7154.	2.5	53
183	K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population. <i>Human Mutation</i> , 2008, 29, 689-694.	2.5	5
184	Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. <i>European Journal of Human Genetics</i> , 2008, 16, 105-114.	2.8	17
185	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443.	27.0	1,180
186	Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 196, 262-269.	0.8	18
187	Systematic, Genome-Wide, Sex-Specific Linkage of Cardiovascular Traits in French Canadians. <i>Hypertension</i> , 2008, 51, 1156-1162.	2.7	53
188	Type 2 Diabetes Without the Atherogenic Metabolic Triad Does Not Predict Angiographically Assessed Coronary Artery Disease in Women. <i>Diabetes Care</i> , 2008, 31, 170-172.	8.6	308
189	Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency. <i>Blood</i> , 2008, 112, 822-822.	1.4	16
190	Association Studies of BMI and Type 2 Diabetes in the Neuropeptide Y Pathway: A Possible Role for NPY2R as a Candidate Gene for Type 2 Diabetes in Men. <i>Diabetes</i> , 2007, 56, 1460-1467.	0.6	52
191	The lipoprotein/lipid profile is modulated by a gene-diet interaction effect between polymorphisms in the liver X receptor-1 $\alpha$ and dietary cholesterol intake in French-Canadians. <i>British Journal of Nutrition</i> , 2007, 97, 11-18.	2.3	28
192	Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. <i>Atherosclerosis</i> , 2007, 190, 429-435.	0.8	31
193	Genetic Analysis of 103 Candidate Genes for Coronary Artery Disease and Associated Phenotypes in a Founder Population Reveals a New Association between Endothelin-1 and High-Density Lipoprotein Cholesterol. <i>American Journal of Human Genetics</i> , 2007, 80, 673-682.	6.2	79
194	Evaluation of Common Variants in the Six Known Maturity-Onset Diabetes of the Young (MODY) Genes for Association With Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 685-693.	0.6	178
195	Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 551-557.	3.3	9
196	Genes, maternal smoking, and the offspring brain and body during adolescence: Design of the Saguenay Youth Study. <i>Human Brain Mapping</i> , 2007, 28, 502-518.	3.6	113
197	Relation of the "Hypertriglyceridemic Waist" Phenotype to Earlier Manifestations of Coronary Artery Disease in Patients With Glucose Intolerance and Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 369-373.	1.6	84
198	Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians. <i>Journal of Molecular Medicine</i> , 2007, 85, 129-137.	3.9	33

#	ARTICLE	IF	CITATIONS
199	A locus on chromosome 10 influences C-reactive protein levels in two independent populations. <i>Human Genetics</i> , 2007, 122, 95-102.	3.8	9
200	Comprehensive Association Testing of Common Mitochondrial DNA Variation in Metabolic Disease. <i>American Journal of Human Genetics</i> , 2006, 79, 54-61.	6.2	173
201	Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2006, 184, 163-170.	0.8	9
202	Common Variants in the ENPP1 Gene Are Not Reproducibly Associated With Diabetes or Obesity. <i>Diabetes</i> , 2006, 55, 3180-3184.	0.6	76
203	The Kruppel-Like Factor 11 (KLF11) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People. <i>Diabetes</i> , 2006, 55, 3620-3624.	0.6	16
204	Common Polymorphisms in the Promoter of the Visfatin Gene (PBEF1) Influence Plasma Insulin Levels in a French-Canadian Population. <i>Diabetes</i> , 2006, 55, 2896-2902.	0.6	76
205	Haplotype Structures and Large-Scale Association Testing of the 5' AMP-Activated Protein Kinase Genes PRKAA2, PRKAB1, and PRKAB2 With Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 849-855.	0.6	28
206	Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1619-1625.	2.4	35
207	High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. <i>Diabetes</i> , 2006, 55, 128-35.	0.6	13
208	Presence of palmar xanthomas in myotonic dystrophy identifies different patterns of linkage disequilibrium between the apolipoprotein E and myotonic dystrophy protein kinase loci. <i>Genetics in Medicine</i> , 2005, 7, 213-215.	2.4	1
209	Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. <i>Journal of Lipid Research</i> , 2005, 46, 237-244.	4.2	42
210	Hyperaldosteronism and Hypertension. <i>Hypertension</i> , 2005, 45, 766-772.	2.7	78
211	Association Testing of the Protein Tyrosine Phosphatase 1B Gene (PTPN1) With Type 2 Diabetes in 7,883 People. <i>Diabetes</i> , 2005, 54, 1884-1891.	0.6	49
212	Genome-Wide Scan for Linkage to Obesity-Associated Hypertension in French Canadians. <i>Hypertension</i> , 2005, 46, 1280-1285.	2.7	39
213	Association Testing of Variants in the Hepatocyte Nuclear Factor 4 Gene With Risk of Type 2 Diabetes in 7,883 People. <i>Diabetes</i> , 2005, 54, 886-892.	0.6	75
214	Association of Common Variation in the HNF1 Gene Region With Risk of Type 2 Diabetes. <i>Diabetes</i> , 2005, 54, 2336-2342.	0.6	73
215	Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management. <i>Canadian Journal of Cardiology</i> , 2005, 21, 199-209.	1.7	5
216	Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). <i>Canadian Journal of Cardiology</i> , 2005, 21, 1187-93.	1.7	28

#	ARTICLE	IF	CITATIONS
217	Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2004, 45, 1077-1083.	4.2	30
218	Association Testing in 9,000 People Fails to Confirm the Association of the Insulin Receptor Substrate-1 G972R Polymorphism With Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, 3313-3318.	0.6	78
219	Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region. <i>Diabetes</i> , 2004, 53, 1360-1368.	0.6	284
220	Diet-Induced Obesity Delays Cardiovascular Recovery from Stress in Spontaneously Hypertensive Rats. <i>Obesity</i> , 2004, 12, 1951-1958.	4.0	28
221	Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. <i>Journal of Human Genetics</i> , 2004, 49, 424-432.	2.3	62
222	Association between the PPAR $\alpha$ -L162V polymorphism and components of the metabolic syndrome. <i>Journal of Human Genetics</i> , 2004, 49, 482-489.	2.3	105
223	Molecular screening of the microsomal triglyceride transfer protein: association between polymorphisms and both abdominal obesity and plasma apolipoprotein B concentration. <i>Journal of Human Genetics</i> , 2004, 49, 684-690.	2.3	15
224	The c.419-420insA in the MTP gene is associated with abetalipoproteinemia among French-Canadians. <i>Molecular Genetics and Metabolism</i> , 2004, 81, 140-143.	1.1	22
225	Visceral obesity attenuates the effect of the hepatic lipase $\alpha^{*}514C>T$ polymorphism on plasma HDL-cholesterol levels in French-Canadian men. <i>Molecular Genetics and Metabolism</i> , 2003, 78, 31-36.	1.1	39
226	Segment of Rat Chromosome 20 Regulates Diet-Induced Augmentations in Adiposity, Glucose Intolerance, and Blood Pressure. <i>Hypertension</i> , 2003, 41, 1047-1055.	2.7	23
227	Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia. <i>Circulation</i> , 2002, 105, 2469-2475.	1.6	440
228	5' Flanking Variants of Resistin Are Associated With Obesity. <i>Diabetes</i> , 2002, 51, 1629-1634.	0.6	158
229	Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein $\alpha^{*}493G/T$ polymorphism on plasma lipoprotein levels in men. <i>Atherosclerosis</i> , 2002, 160, 317-324.	0.8	35
230	Determinants of HDL particle size in patients with the null (P207L) or defective (D9N) mutation in the lipoprotein lipase gene: the Quebec LipD Study. <i>Atherosclerosis</i> , 2002, 162, 269-276.	0.8	8
231	Characterization of LDL Particle Size Among Carriers of a Defective or a Null Mutation in the Lipoprotein Lipase Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1181-1186.	2.4	12
232	Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. <i>American Journal of Cardiology</i> , 2002, 90, 15-18.	1.6	114
233	A Genealogical Study of Essential Hypertension with and without Obesity in French Canadians. <i>Obesity</i> , 2002, 10, 463-470.	4.0	21
234	A Sequence Variation in the Mitochondrial Glycerol-3-Phosphate Dehydrogenase Gene Is Associated with Increased Plasma Glycerol and Free Fatty Acid Concentrations among French Canadians. <i>Molecular Genetics and Metabolism</i> , 2001, 72, 209-217.	1.1	9



#	ARTICLE	IF	CITATIONS
235	In Vivo Variability of TMA Oxidation Is Partially Mediated by Polymorphisms of the FMO3 Gene. <i>Molecular Genetics and Metabolism</i> , 2001, 73, 224-229.	1.1	45
236	Genomewide Linkage Analysis of Stature in Multiple Populations Reveals Several Regions with Evidence of Linkage to Adult Height. <i>American Journal of Human Genetics</i> , 2001, 69, 106-116.	6.2	177
237	Glycerol: a neglected variable in metabolic processes?. <i>BioEssays</i> , 2001, 23, 534-542.	2.5	139
238	Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. <i>Nature Genetics</i> , 2001, 29, 223-228.	21.4	730
239	Arterial Pressure, Left Ventricular Mass, and Aldosterone in Essential Hypertension. <i>Hypertension</i> , 2001, 37, 845-850.	2.7	106
240	Predictors of Target Organ Damage in Hypertensive Blacks and Whites. <i>Hypertension</i> , 2001, 38, 761-766.	2.7	31
241	Heritability Estimates of Obesity Measures in Siblings With and Without Hypertension. <i>Hypertension</i> , 2001, 38, 41-47.	2.7	43
242	Glomerular Hyperfiltration in Hypertensive African Americans. <i>Hypertension</i> , 2000, 35, 822-826.	2.7	60
243	The common PPAR $\alpha$ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. <i>Nature Genetics</i> , 2000, 26, 76-80.	21.4	1,672
244	Role of Tumor Necrosis Factor- $\alpha$ Gene Locus in Obesity and Obesity-Associated Hypertension in French Canadians. <i>Hypertension</i> , 2000, 36, 14-19.	2.7	82
245	Glycerol as a Correlate of Impaired Glucose Tolerance: Dissection of a Complex System by Use of a Simple Genetic Trait. <i>American Journal of Human Genetics</i> , 2000, 66, 1558-1568.	6.2	53
246	Hypertriglyceridemic Waist. <i>Circulation</i> , 2000, 102, 179-184.	1.6	916
247	Procedure to protect confidentiality of familial data in community genetics and genomic research. <i>Clinical Genetics</i> , 1999, 55, 259-264.	2.0	44
248	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. <i>Atherosclerosis</i> , 1999, 143, 145-151.	0.8	22
249	Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. <i>Atherosclerosis</i> , 1999, 143, 153-161.	0.8	50
250	Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. <i>American Journal of Cardiology</i> , 1998, 82, 299-305.	1.6	36
251	Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. <i>Human Mutation</i> , 1998, 11, S226-S231.	2.5	25
252	Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1007-1012.	2.4	80



#	ARTICLE	IF	CITATIONS
253	Relationships of Abdominal Obesity and Hyperinsulinemia to Angiographically Assessed Coronary Artery Disease in Men With Known Mutations in the LDL Receptor Gene. <i>Circulation</i> , 1998, 97, 871-877.	1.6	91
254	1.P.168 Abdominal obesity and hyperinsulinemia as predictors of higher cost of coronary artery bypass grafting among men with or without familial hypercholesterolemia. <i>Atherosclerosis</i> , 1997, 134, 52.	0.8	1
255	Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. <i>Clinical Genetics</i> , 1997, 52, 1-6.	2.0	36
256	Mutations in the Gene for Lipoprotein Lipase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1704-1712.	2.4	39
257	Hypertriglyceridemia and Lower LDL Cholesterol Concentration in Relation to Apolipoprotein E Phenotypes in Myotonic Dystrophy. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 129-133.	0.5	15
258	Myotonic Dystrophy: Linkage with Apolipoprotein E and Estimation of the Gene Carrier Status with Genetic Markers. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 134-140.	0.5	6